HomeCompareTRRGF vs ABBV

TRRGF vs ABBV: Dividend Comparison 2026

TRRGF yields 4000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRRGF wins by $7175340620755.77M in total portfolio value
10 years
TRRGF
TRRGF
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full TRRGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TRRGF vs ABBV

📍 TRRGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRRGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRRGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRRGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRRGF
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TRRGF beats the other by $5,813,155,604,218,139,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRRGF + ABBV for your $10,000?

TRRGF: 50%ABBV: 50%
100% ABBV50/50100% TRRGF
Portfolio after 10yr
$3587670310377.99M
Annual income
$3,419,503,296,598,930,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TRRGF
No analyst data
Altman Z
-8.3
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRRGF buys
0
ABBV buys
0
No recent congressional trades found for TRRGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRRGFABBV
Forward yield4000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7175340620755.87M$102.3K
Annual income after 10y$6,839,006,593,197,835,000.00$24,771.77
Total dividends collected$7152397773804.84M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRRGF vs ABBV ($10,000, DRIP)

YearTRRGF PortfolioTRRGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$410,700$400,000.00$11,550$430.00+$399.1KTRRGF
2$15,792,720$15,353,271.03$13,472$627.96+$15.78MTRRGF
3$568,657,142$551,758,931.89$15,906$926.08+$568.64MTRRGF
4$19,176,207,860$18,567,744,718.20$19,071$1,382.55+$19176.19MTRRGF
5$605,696,028,890$585,177,486,479.73$23,302$2,095.81+$605696.01MTRRGF
6$17,922,210,653,594$17,274,115,902,681.27$29,150$3,237.93+$17922210.62MTRRGF
7$496,869,793,504,300$477,693,028,104,954.00$37,536$5,121.41+$496869793.47MTRRGF
8$12,908,672,105,251,704$12,377,021,426,202,104.00$50,079$8,338.38+$12908672105.20MTRRGF
9$314,330,866,876,668,540$300,518,587,724,049,200.00$69,753$14,065.80+$314330866876.60MTRRGF
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$102,337$24,771.77+$7175340620755.77MTRRGF

TRRGF vs ABBV: Complete Analysis 2026

TRRGFStock

Transatlantic Mining Corp. engages in the acquisition, exploration, and development of mineral properties in the United States. The company has an 80% interest in the Monitor copper-gold project located in the Coeur D'Alene Mining District, Idaho. It also holds an option with lease to acquire a 100% interest in the Miller mine gold project located in Broadwater County of Montana; and a 100% interest in the Golden Jubilee project consisting of 22 unpatented mining claims situated in Granite County, Montana. The company was formerly known as Archean Star Resources Inc. and changed its name to Transatlantic Mining Corp. in February 2014. Transatlantic Mining Corp. was incorporated in 2011 and is headquartered in Vancouver, Canada.

Full TRRGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TRRGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRRGF vs SCHDTRRGF vs JEPITRRGF vs OTRRGF vs KOTRRGF vs MAINTRRGF vs JNJTRRGF vs MRKTRRGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.